Table 1.
Baseline characteristics of patients: tumor, treatment, and outcome
| Patient characteristics (n = 212*) | n/value | % | |
|---|---|---|---|
| Gender | |||
| Female | 96 | 45.3 | |
| Male | 116 | 54.7 | |
| Age at diagnosis | |||
| Median | 63 | – | |
| Range | 19-91 | – | |
| Tumor characteristics (n = 214*) | |||
| Laterality of affected eye | |||
| OD | 103 | 48.1 | |
| OS | 111 | 51.9 | |
| Tumor apical height (mm) | |||
| Mean ±SD | 4.6 ±3.0 | – | |
| Median | 3.3 | – | |
| Range | 1-15 | – | |
| ≤ 2.5 | 70 | 32.7 | |
| > 2-5 | 79 | 36.9 | |
| > 5-10 | 51 | 23.8 | |
| > 10 | 14 | 6.5 | |
| Basal diameter (mm) | |||
| Mean ±SD | 11.5 ±3.2 | – | |
| Median | 11.5 | – | |
| Range | 2-21 | -– | |
| ≤ 8 | 33 | 15.4 | |
| 8-11 | 72 | 33.6 | |
| 11-16 | 93 | 43.5 | |
| > 16 | 16 | 7.5 | |
| AJCC1 staging | |||
| Stage I | 81 | 37.9 | |
| Stage IIA | 60 | 28.0 | |
| Stage IIB | 47 | 22.0 | |
| Stage IIIA | 17 | 7.9 | |
| Stage IIIB | 8 | 3.7 | |
| Stage IIIC | 0 | 0.0 | |
| Stage IV | 1 | 0.5 | |
| COMS2 staging | |||
| Small | 90 | 42.1 | |
| Medium | 81 | 37.9 | |
| Large | 43 | 20.1 | |
| Genetic class | |||
| 1A | 119 | 55.6 | |
| 1B | 30 | 14.0 | |
| 2 | 55 | 25.7 | |
| N.A. | 10 | 4.7 | |
| Treatment characteristics (n = 214*) | |||
| Treatment dose (Gy) | |||
| At height > 5 mm | 85.0 | – | |
| At height ≤ 5 mm | 120.6 | – | |
| % of tumor volume receiving prescription dose | |||
| Mean ±SD | 99.9% ±0.6% | – | |
| Range | 94.9-100% | – | |
| % tumor + 2 mm margin volume receiving prescription dose | |||
| Mean ±SD | 96.8% ±2.8% | – | |
| Range | 85.0-100% | – | |
| Plaque repositioning | |||
| Number of plaques repositioned | 33 | 15.4 | |
| Outcome characteristics (n = 180**) | |||
| Status | |||
| Alive without disease | 150 | 83.3 | |
| Alive with uveal melanoma | 8 | 4.4 | |
| Dead of other or unknown cause | 8 | 4.4 | |
| Dead of uveal melanoma | 14 | 7.8 | |
| Follow-up by ocular oncology | |||
| Mean (months) | 37.3 | – | |
| Median (months) | 30.8 | – | |
| Range (months) | 12.2-96.3 | – | |
| Lost to follow-up | 22 | – | |
| Local control rate | – | 100.0 | |
| Distant metastasis | 22 | 12.2 | |
| Site(s) of distant metastasis | |||
| Liver | 22 | – | |
| Lung | 2 | – | |
| Bone | 3 | – | |
| Spleen | 1 | – | |
| Radiation-related toxicities | |||
| Radiation retinopathy | 85 | 47.2 | |
| Retinal vein occlusion | 9 | 5.0 | |
| Serous retinal detachment | 2 | 1.1 | |
| Vitreous hemorrhage | 2 | 1.1 | |
| Optic neuropathy | 1 | 0.6 | |
| Hypotony maculopathy | 1 | 0.6 | |
| Radiation retinopathy (RR) factors (n = 85) | |||
| Median time to RR (months) | 24 | – | |
| Treated with anti-VEGF or trial | 45 | 52.9 | |
| CTCAE3 grade 1 | 33 | – | |
| CTCAE grade 2 | 13 | – | |
| CTCAE grade 3 | 18 | – | |
| CTCAE grade 4 | 21 | – | |
| CTCAE grade 5 | 0 | – | |
1
8th edition of the American Joint Committee on Cancer, 2 Collaborative ocular melanoma study, 3 Common terminology criteria for adverse events, * One patient presented with two UMs: one OS and one OD treated at separate times. One patient presented with two UMs at separate times within OS, treated at separate times, ** 180 patients had at least 12 months follow-up, for which outcomes are reported